Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Nov 1;25(44):7656-63.
doi: 10.1016/j.vaccine.2007.08.042. Epub 2007 Sep 14.

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

Robert B Couch  1 , Patricia Winokur, Rebecca Brady, Robert Belshe, Wilbur H Chen, Thomas R Cate, Bryndis Sigurdardottir, Amy Hoeper, Irene L Graham, Robert Edelman, Fenhua He, Diane Nino, Jose Capellan, Frederick L Ruben
Affiliations
Clinical Trial

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

Robert B Couch et al. Vaccine. .

Abstract

To improve immune responses to influenza vaccine, a trivalent inactivated vaccine containing 60 microg of the HA of each component (A/H3N2, A/H1N1, B) was compared to a licensed vaccine containing 15 microg of the HA of each. More local and systemic reactions were reported by subjects given the high dosage but only local pain and myalgias were significantly increased. The high dosage vaccine induced a higher frequency of serum antibody increases (> or =4-fold) in both hemagglutination-inhibiting (HAI) and neutralization tests for all three vaccine viruses in the total group as well as subjects vaccinated and those not vaccinated the previous year. Mean titers of antibody attained, the magnitude of antibody increases and the frequencies of persons with final HAI antibody titers > or =1:32, > or =1:64, and > or =1:128 were all greater for the high dosage group in both serologic tests, for all groups, and for all vaccine viruses. These increased immune responses should provide increased protection against influenza in the elderly.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Robert B. Couch has served as a consultant to GlaxoSmithKline, Vaxinnate and Dynavax.

Rebecca Brady receives funding to conduct clinical research studies from GlaxoSmithKline.

Robert Edelman is a consultant to Acambis, Inc.

Robert Belshe is a consultant to Merck and Medimmune, and is a speaker for Merck, Medimmune and sanofi pasteur.

Jose Capellan is an employee and investor of sanofi pasteur

Fred Ruben is an employee and investor of sanofi pasteur

Figures

Figure 1
Figure 1
Fold increase in hemagglutination-inhibiting (HAI) and neutralizing (neut) antibody according to vaccination group, vaccine virus and dosage. H1 = A/New Caledonia (H1N1), H3 – A/Wyoming (H3N2), an A/Fujian-like virus for HAI and A/Fujian (H3N2) for neut, B = B/Jilin. All = total group, previous = vaccinated the previous season (2 to 5 months earlier), not prev vac = not vaccinated the previous season. *Greater than standard dose, p <0.05.
Figure 1
Figure 1
Fold increase in hemagglutination-inhibiting (HAI) and neutralizing (neut) antibody according to vaccination group, vaccine virus and dosage. H1 = A/New Caledonia (H1N1), H3 – A/Wyoming (H3N2), an A/Fujian-like virus for HAI and A/Fujian (H3N2) for neut, B = B/Jilin. All = total group, previous = vaccinated the previous season (2 to 5 months earlier), not prev vac = not vaccinated the previous season. *Greater than standard dose, p <0.05.
See this image and copyright information in PMC

Comment in

  • Influenza vaccine dosages.
    Palache AM, Beyer WE, Osterhaus AD. Palache AM, et al. Vaccine. 2008 May 2;26(19):2305-6. doi: 10.1016/j.vaccine.2008.03.007. Epub 2008 Mar 27. Vaccine. 2008. PMID: 18407384 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002;20:1831–1836. - PubMed
    1. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people; a systematic review. Lancet. 2005;366:1165–1174. - PubMed
    1. Farnik J, Bruj J. An outbreak of influenza A2 in a population with a known antibody profile. J Infect Dis. 1966;116:425–428. - PubMed
    1. Couch RB. An Overview of Serum Antibody Responses to Influenza Virus Antigens. In: Brown F, Haaheim LR, Wood JM, Schild GC, editors. Developments in Biologicals. Vol. 115. Karger: Laboratory Correlates of Immunity to Influenza; 2003. pp. 25–30. - PubMed
    1. Couch RB, Kasel JA. Immunity to influenza in man. Ann Rev Microbiol. 1983;37:529–549. - PubMed

Publication types

MeSH terms

Substances